|
| Authors | Novel prognostic marker | Conclusion |
|
| Li et al. 2015 [39] | The expression patterns of miR-15a/16-1 | miR-15a seems to be linked with disease progression and prognosis while miR-16-1 acts as a valuable diagnostic marker |
| Wang et al. 2015 [40] | Immune checkpoint signaling | The overall response rate to treatment was higher in low sPD-L1 patients than in high sPD-L1 patients |
| Jung et al. 2016 [41] | Inverse platelet to lymphocyte ratio (iPLR) | Staging by iPLR group had predictive value for PFS and OS |
| Zhou et al. 2015 [42] | Dysregulated long noncoding RNAs (lncRNAs) | Four lncRNAs were identified to be significantly associated with OS |
| Lee et al. 2015 [43] | Bone marrow (BM) microvessel density (MVD) | PFS was significantly lower in the high MVD group than in the low MVD group |
| Ma et al. 2015 [44] | N-Cadherin | OS is worse with high expression of N-Cadherin which may be related to 1q21 amplification. |
| Lullo et al. 2015 [45] | Th22 cells | Increased frequency of IL-22(+)IL-17(−)IL-13(+) T cells correlates with poor prognosis |
| Li et al. 2015 [46] | Downregulated miR-33b | miR-33b low expression had significantly shortened PFS and OS |
| Bolomsky et al. 2015 [47] | Insulin-like growth factor binding protein 7 (IGFBP7) expression | IGFBP7 expression is linked to translocation t(4;14) showing clinical features of adverse prognosis |
| Jung et al. 2015 [48] | Autophagic markers beclin 1 and LC3 | Higher immunoreactivity for autophagic markers in MM is associated with superior patient survival |
| Trotter et al. 2015 [49] | Myeloma cell-derived Runx2 | Runx2 expression is a major regulator of MM progression in bone and myeloma bone disease |
|
